Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

Novo Nordisk (NVO) and Viatris (NASDAQ:VTRS) have reportedly reached an agreement in their dispute over U.S. patents ...

Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5.

The appointed independent directors are Dalip Sehgal, former Executive Director at Hindustan Lever Limited and former MD & ...

Stock Market LIVE Updates | Sensex and Nifty began the week on a positive note on Monday, supported by rising information ...

The War That Won’t End: How Oct. 7 Ignited a Year of Conflict As war in the Middle East spreads, the original conflict between Israel and Hamas has persisted. This is why. 11 min read LIVE A ...